Pharmacogenomic study of anthracycline-induced cardiotoxicity in Mexican pediatric patients.

Background: The aim of this study was to evaluate the association between well-defined genetic risk variants in SLC28A3 , RARG and UGT1A6 and anthracycline-induced cardiotoxicity in Mexican pediatric patients. Methods: We tested a cohort of 79 children treated with anthracyclines for the presence of SLC28A3 -rs7853758, RARG -rs2229774 and UGT1A6 -rs17863783. Results: The SLC28A3 -rs7853758 variant was more frequent in this cohort, while the UGT1A6 -rs17863783 and RARG -rs2229774 variants were present at lower frequencies. A clinically important decrease of fractional shortening was associated with SLC28A3 -rs7853758 variant. Conclusion: In this cohort, 39.2% of patients carried the protective SLC28A3 variant. A small number of tested patients have the risk variants of UGT1A6 and RARG . None of the patients shared the two risk variants.